Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 59 Parkinson Disease 4, Autosomal Dominant Lewy Body 25 Lung Neoplasms 25 Squamous Cell Carcinoma of Head and Neck 20 Melanoma 19 Neoplasm Metastasis 18 Neoplasms 16 Endometrial Neoplasms 14 Colorectal Neoplasms 14 Breast Neoplasms 14 Triple Negative Breast Neoplasms 12 Ovarian Neoplasms 11 Head and Neck Neoplasms 9 Carcinoma, Renal Cell 8 Pancreatic Neoplasms 7 Carcinoma, Transitional Cell 7 Urinary Bladder Neoplasms 6 Recurrence 5 Lymphoma 5 Hodgkin Disease 5 Esophageal Neoplasms 4 Carcinoma 4 Brain Neoplasms 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Sarcoma 3 Prostatic Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Fallopian Tube Neoplasms 3

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × pembrolizumab × 30 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡